Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression

Abstract

This study provides a comprehensive evaluation of CLDN18.2 status and its correlation with the clinicopathologic characteristics of patients with stages II-IV GC in Korea and with crucial biomarkers. It may be valuable for guiding future drug development, expanding treatment options, and ultimately improving patient outcomes in GC.